Unibest

Pharmaceutical intermediates

Brigatinib Intermediates

4 pharmaceutical intermediates for Brigatinib. Indication: Non-small cell lung cancer.

提交项目All intermediates

About Brigatinib

Originator
Ariad Pharmaceuticals Inc
Indication
Non-small cell lung cancer
Approved Date
10/02/2017
DS/DP
05/21/2019

Available intermediates

4 intermediates currently listed for Brigatinib. Request specifications, documentation or a quotation for any item below.

Brigatinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-(Dimethylphosphinyl)benzenamine1197953-47-1//
2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl] -4-pyrimidinamine1197953-49-3//
2-Methoxy-4-[4-(4-methylpiperazin -1-yl)piperidin-1-yl]aniline761440-75-9//
1-Methyl-4-(4-piperidyl)piperazine Dihydrochloride;1 -Methyl-4- (piperidin-4-yl)1219979-73-3//

Other programs under B

Baloxavir MarboxilBaricitinibBDTX-1535Bedaquiline FumarateBelumosudil mesylateBelzutifanBempedoic acidBeraprost Sodium

Building toward Brigatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →